Related references
Note: Only part of the references are listed.Histone modifiers: Dynamic regulators of the cutaneous transcriptome
Kanad Ghosh et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2018)
Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study
Gilles Salles et al.
HAEMATOLOGICA (2017)
Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers
Kaiming Sun et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study
Gilles Salles et al.
HAEMATOLOGICA (2017)
CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial
Yasuhiro Oki et al.
HAEMATOLOGICA (2017)
BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia
Jennifer A. Woyach et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
CUDC-907 Promotes Bone Marrow Adipocytic Differentiation Through Inhibition of Histone Deacetylase and Regulation of Cell Cycle
Dalia Ali et al.
STEM CELLS AND DEVELOPMENT (2017)
CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial
Yasuhiro Oki et al.
HAEMATOLOGICA (2017)
B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
Leo Zhang et al.
CLINICAL CANCER RESEARCH (2017)
Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy
Ajay K. Gopal et al.
BLOOD (2017)
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia
Inhye E. Ahn et al.
BLOOD (2017)
Targeting the PI3K/PTEN/AKT/mTOR Pathway in Treatment of Sarcoma Cell Lines
Hui Jun Lim et al.
ANTICANCER RESEARCH (2016)
Idelalisib for the treatment of non-Hodgkin lymphoma
Solomon A. Graf et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
Mantle Cell Lymphoma Is It Time for a New Treatment Paradigm?
Andre Goy
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2016)
Ibrutinib-a new standard treatment for relapsed mantle cell lymphoma?
Peter Martin
LANCET (2016)
Mantle cell lymphoma treatment: plus ca change ...
Peter Martin
LANCET (2016)
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study
Martin Dreyling et al.
LANCET (2016)
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial
Anas Younes et al.
LANCET ONCOLOGY (2016)
Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma
Chan Yoon Cheah et al.
BLOOD (2015)
Functional characterization of BTKC481S mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors
S. Cheng et al.
LEUKEMIA (2015)
Up-regulation of p21WAF1/CIP1 by miRNAs and its implications in bladder cancer cells
Chenghe Wang et al.
FEBS LETTERS (2014)
Pharmacological and genomic profiling identifies NF-kappa B-targeted treatment strategies for mantle cell lymphoma
Rami Rahal et al.
NATURE MEDICINE (2014)
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Ajay K. Gopal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma
David Chiron et al.
CANCER DISCOVERY (2014)
Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS
Takashi Yoshioka et al.
GYNECOLOGIC ONCOLOGY (2013)
Histone Deacetylase Inhibition Promotes Osteoblast Maturation by Altering the Histone H4 Epigenome and Reduces Akt Phosphorylation
Amel Dudakovic et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses
J. E. Bolden et al.
CELL DEATH & DISEASE (2013)
Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor κB pathways
Daniel J. Medina et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
Omar Khan et al.
IMMUNOLOGY AND CELL BIOLOGY (2012)
Phosphorylation/inactivation of PTEN by Akt-independent PI3K signaling in retinal pigment epithelium
Eun Jung Lee et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair
J-H. Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways
Mohamed Rahmani et al.
BLOOD (2009)
The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells
Anna Scuto et al.
BLOOD (2008)
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies
Francis Giles et al.
CLINICAL CANCER RESEARCH (2006)
Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589
DZ Qian et al.
CLINICAL CANCER RESEARCH (2006)
The phosphatidylinositol 3-kinase-AKT pathway in human cancer
I Vivanco et al.
NATURE REVIEWS CANCER (2002)
A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1
ON Ozes et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
